-
Mashup Score: 3The Mayo Clinic’s PragMMatic Study Is Now Accruing Newly Diagnosed Multiple Myeloma Patients - 2 day(s) ago
Mayo Clinic’s PragMMatic Study Accruing Newly Diagnosed Multiple Myeloma Patients A new clinical trial administered by the Mayo Clinic, the PragMMatic Study, is now accruing newly diagnosed multiple myeloma (NDMM) patients. Led by the IMF’s International Myeloma Working Group (IMWG) members Drs. S. Vincent Rajkumar and Shaji Kumar, the study is for the first time comparing the efficacy and side effect profiles of the three most common treatment regimens for NDMM patients. These regimens include the following:
Source: www.myeloma.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0
During a Case-Based Roundtable® event, Abdullah Khan, MBBS, discussed the benefits of using CAR T-cell therapy in patients with relapsed/refractory multiple myeloma in the first article of a 2-part series.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 37Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis - PubMed - 2 day(s) ago
Use of surrogate end-points such as progression-free survival (PFS) and other time-to-event (TTE) end-points is common in multiple myeloma (MM) clinical trials. This systematic review characterises all published randomised controlled trials (RCTs) in MM using PFS or other TTE end-points between 2005 …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 8
Cilta-cel has received approval from the European Commission for multiple myeloma that is relapsed or refractory to at least 1 prior line of therapy.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 26Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma - 7 day(s) ago
Amp(1q), HRCA ≥2, high CTC levels, and a longer time to reach first MRD negativity are significant predictors of unsustained MRD negativity.Maintenance treatmen
Source: ashpublications.orgCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1Another quadruplet therapy for multiple myeloma: the beginning of the end for autologous haematopoietic stem-cell transplantation? - 7 day(s) ago
In the past 15 years, treatment frameworks for newly diagnosed multiple myeloma have radically changed. It is important to recall that as recently as 2010, Rajkumar and colleagues1 presented ECOG E4A03, which was a phase 3 trial examining the role of lenalidomide, combined with two different dosing regimens for dexamethasone, that showed a 68% overall response rate (ORR; 10% complete remission rate) after four cycles of therapy, a result considered to be astounding at the time. Fast forward to 2024, the use of triplet induction has nearly been supplanted by four component regimens, typically including an immunomodulatory drug, a proteasome inhibitor, a steroid, and the newest addition, an anti-CD38 antibody.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 14
Although the study did not achieve the prespecified complete response threshold, Isa-KRd induced deep and durable responses in transplant-eligible patients with newly diagnosed multiple myeloma. The treatment proved safe and consistent with similar regimens in this setting.
Source: www.thelancet.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 106Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk - 8 day(s) ago
Blood Cancer Journal – Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5GPRC5D-Targeted Therapy Continues to be Effective After Dose Reduction in R/R Multiple Myeloma - 9 day(s) ago
At a live virtual event, Leyla Shune, MD, discussed the emergence of talquetamab-tgvs for patients with relapsed/refractory multiple myeloma.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 103Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk - 10 day(s) ago
Blood Cancer Journal – Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
The Mayo Clinic’s PragMMatic Study Is Now Accruing Newly Diagnosed Multiple Myeloma Patients [Nov 27, 2023] @IMFmyeloma https://t.co/tZIrdUhn5U #mmsm @MayoMyeloma @MayoClinic @MayoClinicHS @VincentRK https://t.co/9lUEIRX2zC https://t.co/jkz9XFBQpM